Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
San Antonio, Texas, Estados Unidos
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Have type 2 diabetes
- Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.
- Have a fasting glucose concentration <280 mg/dL at Visit 1
- Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.
- Are between 18 and 70 years of age, inclusive.
- Have body mass index ≥25 kg/m2 and ≤45 kg/m2.
- Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
- Can swallow oral study drug capsule, without splitting or crushing.
Exclusion Criteria:
Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:
- Are breastfeeding.
- Test positive for pregnancy at the time of screening.
- Intend to become pregnant during the study.
- Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.
Treated with any of the following medications:
- Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening
- Alpha-glucosidase inhibitor within 2 months of screening.
- Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.
- Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.
- Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.
- Have a history of renal transplantation or are currently receiving renal dialysis.
- Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.
- Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.
- Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- Have had organ transplantation.
- Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.
- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Secuencia A
|
inyección subcutánea (5 mcg o 10 mcg), dos veces al día
Otros nombres:
administración oral (100 mg), una vez al día por la mañana
Otros nombres:
subcutaneous injection (5mcg or 10mcg), twice a day
oral administration (100mg), once a day in the morning
|
|
Experimental: Secuencia B
|
inyección subcutánea (5 mcg o 10 mcg), dos veces al día
Otros nombres:
administración oral (100 mg), una vez al día por la mañana
Otros nombres:
subcutaneous injection (5mcg or 10mcg), twice a day
oral administration (100mg), once a day in the morning
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Time-averaged Glucose During a 24 Hour Period
Periodo de tiempo: baseline and 8 Weeks
|
Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).
|
baseline and 8 Weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Two-hour Postprandial Glucose After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Fasting Blood Glucose After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Glucagon AUC Excursion After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Triglyceride AUC After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Triglyceride AUC Excursion After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial C-peptide AUC After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial C-peptide AUC Excursion After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Insulin AUC After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Insulin AUC Excursion After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Active GLP-1 AUC After the Morning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal
Periodo de tiempo: baseline and 8 Weeks
|
Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)
|
baseline and 8 Weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)
Periodo de tiempo: 4 Weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
4 Weeks
|
|
Episodes of Hypoglycemia (Baseline to Week 4)
Periodo de tiempo: 4 weeks
|
Number of episodes of hypoglycemia experienced during the first 4 weeks of the study
|
4 weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)
Periodo de tiempo: 8 weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
8 weeks
|
|
Episodes of Hypoglycemia (Week 4 to Week 8)
Periodo de tiempo: 8 weeks
|
Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study
|
8 weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Overall)
Periodo de tiempo: 4 weeks and 8 weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
4 weeks and 8 weeks
|
|
Episodes of Hypoglycemia (Overall)
Periodo de tiempo: 4 weeks and 8 weeks
|
Number of episodes of hypoglycemia experienced overall during the study
|
4 weeks and 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos del metabolismo de la glucosa
- Enfermedades metabólicas
- Enfermedades del sistema endocrino
- Diabetes mellitus
- Diabetes Mellitus, Tipo 2
- Agentes hipoglucemiantes
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Inhibidores de la proteasa
- Agentes contra la obesidad
- Incretinas
- Inhibidores de la dipeptidil-peptidasa IV
- Fosfato de sitagliptina
- Exenatida
Otros números de identificación del estudio
Otros números de identificación del estudio
- H8O-US-GWCV
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .